Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm
NCT06776770
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer (GC-Ib/II)
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Previously Untreated Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Conditions
Gastric Cancer
Interventions
Adebrelimab
Updated 1 time since 2025 Last updated: Jan 10, 2025 Started: Aug 3, 2024 Primary completion: Sep 30, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1/PHASE2 clinical study on Gastric Cancer, this trial is actively recruiting participants. The trial is conducted by Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center and has accumulated 1 data snapshot since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Data source: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
For direct contact, visit the study record on ClinicalTrials.gov .